Mucorales PCR Screening in At-risk Hematology Patients

Inclusion Criteria

• •Underlying disease:
• •* Start of remission induction chemotherapy for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that is newly diagnosed or in first relapse after hematological remission lasting for a minimum duration of 6 months; OR
• •* Start of myeloablative conditioning regimen to prepare for a first allogeneic hematopoietic cell transplantation (HCT).
• •Expected prolonged neutropenia (ANC\< 0.5 x 109 /L for ≥ 7 days).
• •Planned hospital admission for the duration of the neutropenic phase.